Neuropace

Yahoo Finance • 28 days ago

How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. NeuroPace is back on investor radar as analysts update their models and lift the fair value price... Full story

Yahoo Finance • 5 months ago

NeuroPace (NPCE) Q3 2025 Earnings Call Transcript

Image source: The Motley Fool. Date Tuesday, Nov. 4, 2025 at 4:30 p.m. ET Call participants Chief Executive Officer — Joel BeckerChief Financial Officer — Patrick Williams Need a quote from a Motley Fool analyst? Email pr@fool.com Ta... Full story

Yahoo Finance • 5 months ago

After-Hours Gainers: VCYT, RIGL, NPCE, CDNA, And FBLG Post Notable Moves Following Q3 Results

(RTTNews) - Several healthcare and biotech names posted strong after-hours gains on Tuesday following the release of third-quarter earnings and updated guidance for the remainder of 2025. The session was marked by sharp price movements as... Full story

Yahoo Finance • 5 months ago

NeuroPace raises 2025 revenue and gross margin guidance amid record RNS growth and DIXI wind-down

Earnings Call Insights: NeuroPace (NPCE) Q3 2025 MANAGEMENT VIEW * CEO Joel Becker stated the third quarter delivered record results for NeuroPace, with total revenue reaching $27.4 million, representing 30% year-over-year growth. Beck... Full story

Yahoo Finance • 5 months ago

3 Stocks That May Be Priced Below Their Estimated Worth In October 2025

As the United States stock market experiences a period of mostly positive momentum, with major indices like the S&P 500 and Nasdaq on track for weekly and monthly gains, investors are keenly observing opportunities that may arise from thes... Full story

Yahoo Finance • 6 months ago

3 Companies That May Be Priced Below Their Estimated Value

As the United States stock market navigates uncertainties such as potential government shutdowns and fluctuating commodity prices, major indices like the Dow Jones, Nasdaq, and S&P 500 have shown resilience with recent gains. In this envir... Full story

Yahoo Finance • 8 months ago

NeuroPace raises 2025 revenue guidance to $94M-$98M as RNS System drives record growth

Earnings Call Insights: NeuroPace, Inc. (NPCE) Q2 2025 MANAGEMENT VIEW * CEO Joel D. Becker highlighted a “record revenue quarter with strong revenue of $23.5 million, representing 22% growth compared to $19.3 million in the prior year... Full story

Yahoo Finance • 9 months ago

NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025

MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the... Full story

Yahoo Finance • 9 months ago

NeuroPace's SWOT analysis: innovative epilepsy treatment stock faces growth hurdles

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company with a market capitalization of $341 million specializing in responsive neurostimulation for epilepsy treatment, has been making waves in the healthcare sector with its innovative RNS... Full story

Yahoo Finance • 10 months ago

NeuroPace stock rating reiterated at Overweight by Cantor Fitzgerald

Investing.com - Cantor Fitzgerald maintained its Overweight rating and $16.00 price target on NeuroPace Inc (NASDAQ:NPCE) on Monday following the company’s announcement of a new chief financial officer. NeuroPace announced Monday the appo... Full story

Yahoo Finance • 10 months ago

NeuroPace appoints Patrick Williams as CFO

* NeuroPace (NASDAQ:NPCE [https://seekingalpha.com/symbol/NPCE]) has announced the appointment of Mr. Patrick F. Williams as CFO, effective June 20, 2025 [https://seekingalpha.com/pr/20146644-neuropace-announces-strategic-cfo-transition]... Full story

Yahoo Finance • 10 months ago

NeuroPace Announces Strategic CFO Transition

Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, Calif., June 24, 20... Full story

Yahoo Finance • 10 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE).  Such investors are advised to contact Danielle Peyton at newacti... Full story

Yahoo Finance • 10 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE).  Such investors are advised to contact Danielle Peyton at newacti... Full story

Yahoo Finance • 10 months ago

NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey

NeuroPace, Inc. (NASDAQ:NPCE) is among the best NASDAQ stocks under $50 to buy. Cantor Fitzgerald reiterated its Overweight rating on NeuroPace, Inc. (NASDAQ:NPCE), with a price target of $16.00, implying an upside of nearly 44%. This affi... Full story

Yahoo Finance • 10 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, Inc. - NPCE

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE).  Such investors are advised to contact Danielle Peyton at newacti... Full story

Yahoo Finance • 11 months ago

NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary saf... Full story

Yahoo Finance • last year

NeuroPace Provides Update on Tariff Status

-- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a... Full story

Yahoo Finance • last year

NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results

-- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million -- -- Completed an underwritten public offering of $74.8 million, using $49.5 million of the net proceeds to repurchase 1... Full story

Yahoo Finance • last year

UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference

MOUNTAIN VIEW, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at... Full story